Pharmaceutical compositions

a composition and composition technology, applied in the field of pharmaceutical compositions for oral administration, can solve the problems of unable to improve intestinal drug absorption, lose its potential bioadhesive and absorption enhancing properties, and the composition that meets these requirements is a significant challenge, so as to achieve the effect of enhancing the absorption of the drug

Inactive Publication Date: 2006-06-01
ARCHIMEDES DEVMENT
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018] We have found that combining a drug compound with chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan and an organic acid in a solid composition can enhance absorption of the drug in certain environments within the gastrointestinal tract of animals such as humans.

Problems solved by technology

To prepare a solid chitosan containing composition that meets these requirements represents a significant challenge.
At neutral and basic pH values, chitosan loses its charge and precipitates from solution, thus losing its potential bioadhesive and absorption enhancing properties.
However, the chitosan will remain undissolved and thus unable to improve intestinal drug absorption.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions
  • Pharmaceutical compositions
  • Pharmaceutical compositions

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation and Dissolution Testing of Chitosan Tablets

[0075] A powder blend was prepared by mixing together 20 grams of chitosan (ChitoClear®, Primex, Haugesund, Norway) and 80 grams of mannitol (Pearlitol SD200, Roquette, Lestrem, France). The chitosan had a degree of deacetylation of 93% and an approximate average molecular weight of 200,000 Da. The powder blend was compressed using a Manesty F3 tablet press (from Manesty, Liverpool, UK) fitted with 9 mm diameter circular tooling to produce tablets.

[0076] The dissolution of the tablets was measured in pH 7.4 HEPES buffer at 37° C. using United States Pharmacopeia Method II (USP26 / NF21, United States Pharmacopeia Convention, Rockville, Md., USA, 2002) with paddles at 100 rpm. 250 ml of buffer was used in each dissolution beaker.

[0077] Samples of dissolution medium were collected at periodic intervals up to 240 minutes, filtered (0.45 μm) and measured for chitosan content using a ninhydrin assay.

[0078] To perform the chitosan a...

example 2

Preparation of Succinic Acid / Sodium Salicylate Pellets

[0080] 220 grams of microcrystalline cellulose (Avicel PH101, FMC, Philadelphia, USA), 200 grams of succinic acid (Sigma) and 20 grams of sodium salicylate (Fluka, Buchs, Switzerland) were added to the bowl of a Kenwood food mixer. The mixture was blended for 3 minutes at 60 rpm. Water was added gradually while mixing to granulate the blend. When the granulate was deemed to have reached a consistency suitable for extrusion (230 ml water added), addition was stopped and mixing continued for a further 10 minutes. The material was then extruded using a Caleva Model 10 extruder (Caleva, Sturminster Newton, Dorest, UK) at 15 rpm. The diameter of the holes on the extruder was 1 mm. The extrudate was then spheronised in approximately 45 gram batches using a Caleva Model 120 spheroniser (Caleva, Sturminster Newton, Dorest, UK) for 10 minutes at setting 75 (2250 rpm). The pellets were dried overnight in an oven at 50° C. The final yield ...

example 3

Preparation of Coated Succinic Acid / Sodium Salicylate Pellets

[0081] 150 ml of water was heated to approximately 80° C. 10 grams of hydroxypropyl methylcellulose (Methocel E5 LV, Colorcon, Orpington, UK) was dispersed into the hot water. The dispersion was cooled in an ice bath while stirring until a clear solution had formed. The solution was made up to 200 ml with water.

[0082] The pellets produced in Example 2 were sieved and the fraction between 0.71 and 1.00 mm collected (251 grams). 200 grams of these pellets were placed into the coating chamber of an Aeromatic STREA-1 fluidised bed coater (bottom spray) (Niro Aeromatic, Bubendorf, Switzerland). The Methocel solution was applied to the pellets at a coating temperature of 60° C. and application rate of 1.5 grams / minute. 175 ml of coating solution was applied giving a theoretical HPMC content in the final pellets of 4.4% w / w.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

The present invention provides a solid composition for oral administration comprising: (i) a drug compound; (ii) chitosan or a derivative thereof or a salt of chitosan or salt of a derivative of chitosan; and (iii) an organic acid. Preferably the drug compound is a polar molecule having a molecular weight of 1 KDa or less, a peptide, a protein or a polysaccharide. The compositions of the invention provide enhance absorption of the drug compound.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of International Application No. PCT / GB2004 / 002057, filed May 13, 2004, which was published in the English language on Nov. 25, 2004, under International Publication No. WO 2004 / 100941 A1, the disclosure of which is incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] This invention relates to pharmaceutical compositions for oral administration comprising a drug compound, chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan and an organic acid. [0003] The oral route is the preferred means by which drugs are administered to humans and animals due to its convenience, simplicity and acceptability to patients. Most conventional drugs are well absorbed from the intestines, usually by a process of passive absorption, although certain compounds are taken up by more specific means such as facilitated or active transport. Small polar molecules often display...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/28A61K38/22A61K38/21A61K38/20A61K38/19A61K38/18A61K9/48A61K9/16A61K9/20A61K9/50A61K31/19A61K31/722A61K38/00
CPCA61K9/1617A61K9/1652A61K9/205A61K9/4808A61K9/5047A61K9/5084A61K31/19A61K31/722A61K38/00A61P43/00
Inventor LEANE, MICHAELSMITH, ALANILLUM, LISBETH
Owner ARCHIMEDES DEVMENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap